Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.

US FDA grants orphan drug designation to Sanofi’s riliprubart for antibody-mediated rejection in solid organ transplantation: Paris Thursday, June 26, 2025, 09:00 Hrs [IST] The ...

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and ...

Shares of Neuren Pharmaceuticals Ltd (ASX:NEU) jumped over 10% on Thursday after the company announced a key development in ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...

The market may be having a subdued start to the day but that hasn't stopped two ASX healthcare stocks from racing higher. Let ...

Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $ ...

Phil Tennant, chief commercial officer at cell and gene therapy biotech Precigen, discusses the use of AI in the company’s latest RRP awareness campaign.

These shares are having a strong session on Thursday. But why? The post Why DroneShield, Neuren, Paradigm, and Pilbara ...